Cargando…

Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

OBJECTIVE: To assess the efficacy and safety of nivolumab for advanced renal cell carcinoma (RCC) via meta-analysis. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, Science Citation Index Expanded, The Cochrane Library, and Web of Science for randomized controlled t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Siqi, Xu, Xiaohua, Chen, Jiaqi, Zhang, Zhiping, Liu, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975659/ https://www.ncbi.nlm.nih.gov/pubmed/35368898 http://dx.doi.org/10.1155/2022/5430525

Ejemplares similares

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
por: Jin, Conghui, et al.
Publicado: (2016)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
por: Tella, Sri Harsha, et al.
Publicado: (2019)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Efficacy and safety of perioperative appliance of sunitinib in patients with metastatic or advanced renal cell carcinoma: A systematic review and meta-analysis
por: Jin, Hongyu, et al.
Publicado: (2019)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
por: Gamulin, Marija, et al.
Publicado: (2020)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
por: Chen, Jingjie, et al.
Publicado: (2020)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
por: George, Daniel J, et al.
Publicado: (2022)

Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
por: Shao, Ning, et al.
Publicado: (2019)

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
por: Matsumoto, Toshihiko, et al.
Publicado: (2020)

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials
por: Zhang, Yixin, et al.
Publicado: (2022)

The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
por: Huang, Jiaxing, et al.
Publicado: (2016)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
por: Wu, Bin, et al.
Publicado: (2018)

Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Li, Dailong, et al.
Publicado: (2023)

The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Yiu, Wingkeung, et al.
Publicado: (2022)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
por: Vitale, Maria Giuseppa, et al.
Publicado: (2018)

Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Xu, Zheng, et al.
Publicado: (2019)

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
por: McCrea, Charles, et al.
Publicado: (2018)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Efficacy and safety of intermittent vs continuous furosemide for heart failure concomitant renal dysfunction: A protocol for systematic review and meta-analysis
por: Chen, Siqi, et al.
Publicado: (2021)

A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma
por: Qu, Hongchen, et al.
Publicado: (2022)

Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma
por: Niwa, Kazutomo, et al.
Publicado: (2020)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
por: Tykodi, Scott S, et al.
Publicado: (2022)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis
por: He, Qian, et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
por: Xu, Hang, et al.
Publicado: (2019)

Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis
por: Liu, Xiu-Lan, et al.
Publicado: (2020)

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
por: Toor, Kabirraaj, et al.
Publicado: (2021)

The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma
por: Kim, Han Sang, et al.
Publicado: (2022)

Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
por: Omae, Kenji, et al.
Publicado: (2017)

Comparative efficacy and safety of analgesics for acute renal colic: A network meta-analysis protocol
por: Fu, Shimin, et al.
Publicado: (2019)

Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review
por: Ansari, Jawaher, et al.
Publicado: (2018)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_komp58sojv7ppq8gv42daimia4